These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 17276501)

  • 1. Anticancer and chemosensitizing effects of 2,3-DCPE in ovarian carcinoma cell lines: link with ERK activation and modulation of p21WAF1/CIP1, Bcl-2 and Bcl-xL expression.
    Villedieu M; Briand M; Duval M; Héron JF; Gauduchon P; Poulain L
    Gynecol Oncol; 2007 May; 105(2):373-84. PubMed ID: 17276501
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Absence of Bcl-xL down-regulation in response to cisplatin is associated with chemoresistance in ovarian carcinoma cells.
    Villedieu M; Louis MH; Dutoit S; Brotin E; Lincet H; Duigou F; Staedel C; Gauduchon P; Poulain L
    Gynecol Oncol; 2007 Apr; 105(1):31-44. PubMed ID: 17275076
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Induction of S-phase arrest and p21 overexpression by a small molecule 2[[3-(2,3-dichlorophenoxy)propyl] amino]ethanol in correlation with activation of ERK.
    Zhu H; Zhang L; Wu S; Teraishi F; Davis JJ; Jacob D; Fang B
    Oncogene; 2004 Jun; 23(29):4984-92. PubMed ID: 15122344
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mcl-1 is an important determinant of the apoptotic response to the BH3-mimetic molecule HA14-1 in cisplatin-resistant ovarian carcinoma cells.
    Simonin K; Brotin E; Dufort S; Dutoit S; Goux D; N'diaye M; Denoyelle C; Gauduchon P; Poulain L
    Mol Cancer Ther; 2009 Nov; 8(11):3162-70. PubMed ID: 19887550
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Induction of apoptosis and down-regulation of Bcl-XL in cancer cells by a novel small molecule, 2[[3-(2,3-dichlorophenoxy)propyl]amino]ethanol.
    Wu S; Zhu H; Gu J; Zhang L; Teraishi F; Davis JJ; Jacob DA; Fang B
    Cancer Res; 2004 Feb; 64(3):1110-3. PubMed ID: 14871845
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Acquisition of chemoresistance following discontinuous exposures to cisplatin is associated in ovarian carcinoma cells with progressive alteration of FAK, ERK and p38 activation in response to treatment.
    Villedieu M; Deslandes E; Duval M; Héron JF; Gauduchon P; Poulain L
    Gynecol Oncol; 2006 Jun; 101(3):507-19. PubMed ID: 16387351
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bcl-XL and MCL-1 constitute pertinent targets in ovarian carcinoma and their concomitant inhibition is sufficient to induce apoptosis.
    Brotin E; Meryet-Figuière M; Simonin K; Duval RE; Villedieu M; Leroy-Dudal J; Saison-Behmoaras E; Gauduchon P; Denoyelle C; Poulain L
    Int J Cancer; 2010 Feb; 126(4):885-95. PubMed ID: 19634140
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Costunolide induces apoptosis in platinum-resistant human ovarian cancer cells by generating reactive oxygen species.
    Yang YI; Kim JH; Lee KT; Choi JH
    Gynecol Oncol; 2011 Dec; 123(3):588-96. PubMed ID: 21945308
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bcl-xL is expressed in ovarian carcinoma and modulates chemotherapy-induced apoptosis.
    Liu JR; Fletcher B; Page C; Hu C; Nunez G; Baker V
    Gynecol Oncol; 1998 Sep; 70(3):398-403. PubMed ID: 9790794
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Chemotherapy resistance induced by interleukin-6 in ovarian cancer cells and its signal transduction pathways].
    Wang Y; Li LZ; Ye L; Niu XL; Liu X; Zhu YQ; Sun WJ; Liang YJ
    Zhonghua Fu Chan Ke Za Zhi; 2010 Sep; 45(9):691-8. PubMed ID: 21092551
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Bcl-2/Bcl-XL family inhibitor ABT-737 sensitizes ovarian cancer cells to carboplatin.
    Witham J; Valenti MR; De-Haven-Brandon AK; Vidot S; Eccles SA; Kaye SB; Richardson A
    Clin Cancer Res; 2007 Dec; 13(23):7191-8. PubMed ID: 18056200
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Proliferation inhibition and apoptosis onset in human ovarian carcinoma cell line SKOV3 induced by Genistein].
    Li Y; Mi C
    Ai Zheng; 2003 Jun; 22(6):586-91. PubMed ID: 12948406
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expression of p53 in cisplatin-resistant ovarian cancer cell lines: modulation with the novel platinum analogue (1R, 2R-diaminocyclohexane)(trans-diacetato)(dichloro)-platinum(IV).
    Hagopian GS; Mills GB; Khokhar AR; Bast RC; Siddik ZH
    Clin Cancer Res; 1999 Mar; 5(3):655-63. PubMed ID: 10100719
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lack of multicellular drug resistance observed in human ovarian and prostate carcinoma treated with the proteasome inhibitor PS-341.
    Frankel A; Man S; Elliott P; Adams J; Kerbel RS
    Clin Cancer Res; 2000 Sep; 6(9):3719-28. PubMed ID: 10999766
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lipoic acid decreases Mcl-1, Bcl-xL and up regulates Bim on ovarian carcinoma cells leading to cell death.
    Kafara P; Icard P; Guillamin M; Schwartz L; Lincet H
    J Ovarian Res; 2015 Jun; 8():36. PubMed ID: 26063499
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Time-dependent changes in factors involved in the apoptotic process in human ovarian cancer cells as a response to cisplatin.
    Kolfschoten GM; Hulscher TM; Schrier SM; van Houten VM; Pinedo HM; Boven E
    Gynecol Oncol; 2002 Mar; 84(3):404-12. PubMed ID: 11855878
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Regulation of p53 target gene expression by cisplatin-induced extracellular signal-regulated kinase.
    DeHaan RD; Yazlovitskaya EM; Persons DL
    Cancer Chemother Pharmacol; 2001 Nov; 48(5):383-8. PubMed ID: 11761456
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Induction of apoptosis by metformin in epithelial ovarian cancer: involvement of the Bcl-2 family proteins.
    Yasmeen A; Beauchamp MC; Piura E; Segal E; Pollak M; Gotlieb WH
    Gynecol Oncol; 2011 Jun; 121(3):492-8. PubMed ID: 21388661
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Synergistic efficacy of a novel combination therapy controls growth of Bcl-x(L) bountiful neuroblastoma cells by increasing differentiation and apoptosis.
    Mohan N; Banik NL; Ray SK
    Cancer Biol Ther; 2011 Nov; 12(9):846-54. PubMed ID: 21878749
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of the Raf-MEK1/2-ERK1/2 signaling pathway, Bcl-xL down-regulation, and chemosensitization of non-Hodgkin's lymphoma B cells by Rituximab.
    Jazirehi AR; Vega MI; Chatterjee D; Goodglick L; Bonavida B
    Cancer Res; 2004 Oct; 64(19):7117-26. PubMed ID: 15466208
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.